These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 34218776

  • 1. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J.
    Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A, Tolebrutinib Phase 2b Study Group.
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [Abstract] [Full Text] [Related]

  • 3. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 4. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
    Saberi D, Geladaris A, Dybowski S, Weber MS.
    Expert Opin Ther Targets; 2023 Jun 20; 27(4-5):347-359. PubMed ID: 37272515
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S, Pretzsch R, Häusler D, Haselmayer P, Grenningloh R, Boschert U, Brück W, Weber MS.
    Acta Neuropathol; 2020 Oct 20; 140(4):535-548. PubMed ID: 32761407
    [Abstract] [Full Text] [Related]

  • 6. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E, Correale J.
    Drug Des Devel Ther; 2022 Oct 20; 16():3473-3490. PubMed ID: 36238195
    [Abstract] [Full Text] [Related]

  • 7. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R, Oh J.
    Curr Neurol Neurosci Rep; 2022 Nov 20; 22(11):721-734. PubMed ID: 36301434
    [Abstract] [Full Text] [Related]

  • 8. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
    Krämer J, Wiendl H.
    Curr Opin Neurol; 2024 Jun 01; 37(3):237-244. PubMed ID: 38533819
    [Abstract] [Full Text] [Related]

  • 9. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H.
    Ther Adv Neurol Disord; 2024 Jun 01; 17():17562864241233041. PubMed ID: 38638671
    [Abstract] [Full Text] [Related]

  • 10. Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.
    Turner TJ, Brun P, Gruber RC, Ofengeim D.
    Drugs R D; 2024 Jun 01; 24(2):263-274. PubMed ID: 38965189
    [Abstract] [Full Text] [Related]

  • 11. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
    García-Merino A.
    Cells; 2021 Sep 27; 10(10):. PubMed ID: 34685540
    [Abstract] [Full Text] [Related]

  • 12. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis.
    Steinmaurer A, Riedl C, König T, Testa G, Köck U, Bauer J, Lassmann H, Höftberger R, Berger T, Wimmer I, Hametner S.
    Brain Pathol; 2024 Sep 27; 34(5):e13240. PubMed ID: 38254312
    [Abstract] [Full Text] [Related]

  • 13. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
    Geladaris A, Torke S, Weber MS.
    CNS Drugs; 2022 Oct 27; 36(10):1019-1030. PubMed ID: 36178589
    [Abstract] [Full Text] [Related]

  • 14. Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.
    Tavakoli GM, Yazdanpanah N, Rezaei N.
    Adv Rheumatol; 2024 Aug 21; 64(1):61. PubMed ID: 39169436
    [Abstract] [Full Text] [Related]

  • 15. Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.
    Rijvers L, van Langelaar J, Bogers L, Melief MJ, Koetzier SC, Blok KM, Wierenga-Wolf AF, de Vries HE, Rip J, Corneth OB, Hendriks RW, Grenningloh R, Boschert U, Smolders J, van Luijn MM.
    JCI Insight; 2022 Aug 22; 7(16):. PubMed ID: 35852869
    [Abstract] [Full Text] [Related]

  • 16. Unraveling the Role of the Glycogen Synthase Kinase-3β, Bruton's Tyrosine Kinase, and Sphingosine 1 Phosphate Pathways in Multiple Sclerosis.
    Mohite R, Gharat S, Doshi G.
    Endocr Metab Immune Disord Drug Targets; 2024 Aug 22; 24(10):1131-1145. PubMed ID: 38284723
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
    Torke S, Weber MS.
    Expert Opin Investig Drugs; 2020 Oct 22; 29(10):1143-1150. PubMed ID: 32772592
    [Abstract] [Full Text] [Related]

  • 18. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
    Evonuk KS, Wang S, Mattie J, Cracchiolo CJ, Mager R, Ferenčić Ž, Sprague E, Carrier B, Schofield K, Martinez E, Stewart Z, Petrosino T, Johnson GA, Yusuf I, Plaisted W, Naiman Z, Delp T, Carter L, Marušić S.
    Acta Neuropathol Commun; 2023 Jul 12; 11(1):115. PubMed ID: 37438842
    [Abstract] [Full Text] [Related]

  • 19. Bruton's tyrosine kinase: A promising target for treating systemic lupus erythematosus.
    Ding Q, Zhou Y, Feng Y, Sun L, Zhang T.
    Int Immunopharmacol; 2024 Dec 05; 142(Pt A):113040. PubMed ID: 39216117
    [Abstract] [Full Text] [Related]

  • 20. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review.
    Dybowski S, Torke S, Weber MS.
    JAMA Neurol; 2023 Apr 01; 80(4):404-414. PubMed ID: 36780171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.